Fierce Pharma

GSK's ViiV confirms staying power of long-acting HIV treatment Cabenuva in adolescents

As GSK’s HIV unit ViiV Healthcare grapples with a new rival in the injectable HIV prevention and treatment field, the company is reinforcing the staying power of its long-acting treatment Cabenuva | ...
MedPage Today on MSN

Injectable ART Suppressed HIV Long-Term in Teens

Despite injection-site reactions, teens strongly preferred injectables to daily oral optio ...
Fierce Pharma

Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel

Ascendis Pharma is spiraling upward by way of its TransCon platform. | Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based ...
NPR

Life Kit

Everyone needs a little help being a human. From sleep to saving money to parenting and more, host Marielle Segarra talks to experts to get the best advice out there. Life Kit is here to help you get ...
pharmaphorum

GSK sees £20bn peak sales potential in late-stage pipeline

GlaxoSmithKline's pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial ...
pharmaphorum

CHMP backs Lilly’s Baqsimi as non-injectable for severe low blood sugar

The EMA’s human medicines advisory committee has recommended approval of Eli Lilly’s Baqsimi as the first needle-free treatment for severe low blood sugar levels (hypoglycaemia) in diabetics in the EU ...